Dermatitis Therapeutic Pipeline Review H1 2015
Past News Releases
RSSDallas, Texas (PRWEB) April 21, 2015
The report “Dermatitis – Pipeline Review, H1 2015” provides comparative analysis on the therapeutic development for Dermatitis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/dermatitis-pipeline-review-h1-2015-market-report.html .
The report also reviews key players involved in the therapeutic development for Dermatitis and special features on late-stage and discontinued projects. Companies discussed in this Dermatitis – Pipeline Review, H1 2015 report include AlbireoPharma, Amorepacific Corporation, Anacor Pharmaceuticals, Inc., AnaMar AB, AnaptysBio, Inc., AnGes MG, Inc., Aquinox Pharmaceuticals Inc., arGEN-X BV, Biomar Microbial Technologies, Blueberry Therapeutics Ltd, Brickell Biotech, Inc., Bristol-Myers Squibb Company, Celgene Corporation, Celsus Therapeutics Plc, ChemoCentryx, Inc., China Biologic Products, Inc., ChironWells GmbH, Chugai Pharmaceutical Co., Ltd., Circassia Pharmaceuticals plc, Convoy Therapeutics, Inc., Creabilis SA, Daiichi Sankyo Company, Limited, Dermira Inc., Eisai Co., Ltd., EpiPharm AG, F. Hoffmann-La Roche Ltd., FAES Farma SA, Foamix Pharmaceuticals Ltd., Fountain Biopharma Inc., GlaxoSmithKline plc, GlycaNova Norway AS, Grupo Ferrer Internacional, S.A., Han Wha Pharma Co., Ltd., HanAll Biopharma Co., Ltd., Herantis Pharma plc., IMMD Inc., Immune Response BioPharma, Inc., Inflamalps SA, Janssen Research & Development, LLC, Johnson & Johnson, Kyowa Hakko Kirin Co., Ltd., LegoChem Biosciences, Inc, LEO Pharma A/S, Lixte Biotechnology Holdings, Inc., Madam Therapeutics B.V., Marinomed Biotechnologie GmbH, Maruho Co., Ltd., MedImmune, LLC, Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Nabriva Therapeutics AG, NeoPharm Co., Ltd., Novan, Inc., Novartis AG, Nuvo Research Inc., Otsuka Holdings Co., Ltd., Oxagen Limited, Pergamum AB, Pfizer Inc., Pharis Biotec GmbH, Pharmedartis GmbH, Phosphagenics Limited, ProCertus BioPharm Inc., Promius Pharma, LLC, Provectus Biopharmaceuticals, Inc., R-Tech Ueno, Ltd., Reata Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., RestorGenex Corporation, Stemnion, Inc, sterna biologicals Gmbh & Co KG, Sun Pharma Advanced Research Company Ltd., SWITCH Biotech LLC, Taisho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Thesan Pharmaceuticals, Inc., Upsher-Smith Laboratories, Inc., Valeant Pharmaceuticals International, Inc., Vicore Pharma AB, Vida Therapeutics Inc., Vitae Pharmaceuticals, Inc., VivaCell Biotechnology Espana S.L., Welichem Biotech Inc., XBiotech USA, Inc., Xencor, Inc., Yungjin Pharm Ind. Co., Ltd. and Ziarco Pharma Ltd.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Order a purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=365305 . (This is a premium report priced at US$2000 for a single user License.)
List of Tables
Number of Products under Development for Dermatitis, H1 2015 23
Number of Products under Development for Dermatitis - Comparative Analysis, H1 2015 24
Number of Products under Development by Companies, H1 2015 26
Number of Products under Development by Companies, H1 2015 (Contd..1) 27
Number of Products under Development by Companies, H1 2015 (Contd..2) 28
Number of Products under Development by Companies, H1 2015 (Contd..3) 29
Number of Products under Development by Companies, H1 2015 (Contd..4) 30
Number of Products under Development by Companies, H1 2015 (Contd..5) 31
Number of Products under Development by Companies, H1 2015 (Contd..6) 32
Number of Products under Investigation by Universities/Institutes, H1 2015 33
Comparative Analysis by Late Stage Development, H1 2015 34
Comparative Analysis by Clinical Stage Development, H1 2015 35
Comparative Analysis by Early Stage Development, H1 2015 36
Comparative Analysis by Unknown Stage Development, H1 2015 37
Products under Development by Companies, H1 2015 38
Products under Investigation by Universities/Institutes, H1 2015 47
List of Figures
Number of Products under Development for Dermatitis, H1 2015 23
Number of Products under Development for Dermatitis - Comparative Analysis, H1 2015 24
Number of Products under Development by Companies, H1 2015 25
Number of Products under Investigation by Universities/Institutes, H1 2015 33
Comparative Analysis by Late Stage Development, H1 2015 34
Comparative Analysis by Clinical Stage Development, H1 2015 35
Comparative Analysis by Early Stage Products, H1 2015 36
Assessment by Monotherapy Products, H1 2015 135
Number of Products by Top 10 Targets, H1 2015 136
Number of Products by Stage and Top 10 Targets, H1 2015 136
Number of Products by Top 10 Mechanism of Actions, H1 2015 140
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 140
Number of Products by Top 10 Routes of Administration, H1 2015 143
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 144
Number of Products by Top 10 Molecule Types, H1 2015 145
Number of Products by Stage and Top 10 Molecule Types, H1 2015 145
Explore more reports on Dermatology therapeutics industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/dermatology-therapeutics .
About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.